Compugen Ltd.
HealthcareNASDAQ:CGEN · NASDAQ Global Market
+$0.00 today
Vol 0.21M · Avg 0.48M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
34.4%
avg -41.0%
ROIC
23.2%
avg -36.6%
ROA
22.5%
avg -31.1%
Analysis
ROE is currently the strongest return metric at 34.4% versus its period average of -41.0%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Anat Cohen-Dayag | Executive Chair | $743,145.00 | — | 59 | — | — |
Michelle Mahler | Chief Medical Officer | $581,767.00 | — | — | $23,125.00 | 0.02% |
Pierre Ferre | Chief Operating Officer | $471,409.00 | — | 49 | — | — |
Eran Ophir | Chief Executive Officer, President & Director | $312,235.00 | — | 48 | $11,375.00 | 0.01% |
Zurit Levine | Senior Vice President of Business Development | $303,697.00 | — | 58 | $31,375.00 | 0.03% |
David Silberman | Chief Financial Officer | — | — | 42 | $35,500.00 | 0.04% |
Eran Ben Dor | General Counsel & Corporate Secretary | — | — | — | $11,375.00 | 0.01% |
Dorit Amitay | Vice President of Human Resources | — | — | 58 | — | — |
Sharon Kredo-Russo | Senior Vice President of Research & Discovery | — | — | 46 | $19,500.00 | 0.02% |
Rivka Schwartz | Vice President Research and Discovery | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
10
$113,591.19
Net Sentiment
$113,591.19
Net selling
Most Active
Levine Zurit
7 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 10 sells worth $113,591.19 over the last 12 months. That adds up to net selling of $113,591.19. Levine Zurit was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +237.2% | +9.5% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +237.2% over three years. Forward estimates point to Revenue at +9.5% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Nuvectis Pharma, Inc.
NASDAQ:NVCT
$284.09M
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
$180.93M
Innate Pharma S.A.
NASDAQ:IPHA
$165.27M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
Cassava Sciences, Inc.
SAVA
$63.77M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$49.65M
Who manages CGEN?
Compugen Ltd. (CGEN) lists 10 active executives. The top listed executive is Anat Cohen-Dayag, Executive Chair.
Are CGEN insiders buying or selling?
Recent insider activity shows net selling of $113,591.19.
Explore More
Continue the stock analysis
Jump to another research area for this company.